Merck to acquire verona pharma, expanding its portfolio to include ohtuvayre® (ensifentrine), a first-in-class copd maintenance treatment for adults and expected to drive growth into the next decade

Rahway, n.j. & raleigh, n.c.--(business wire)--merck (nyse: mrk), known as msd outside of the united states and canada, and verona pharma plc (nasdaq: vrna) (“verona pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which merck, through a subsidiary, will acquire verona pharma for $107 per american depository share (ads), each of which represents eight verona pharma ordinary shares, for a tota.
VRNA Ratings Summary
VRNA Quant Ranking